On January 26, 2023, the Food and Drug Administration (Agency) announced that the existing regulatory frameworks are not appropriate for CBD products. Thus, the Agency called on Congress to develop a regulatory pathway that “balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.” In reaching its decision, the Agency reasoned that “FDA’s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products,” recognizing that CBD raises various safety concerns, including potential harm to the liver and male reproductive system, and possible interactions with certain medications. Read the full announcement here.
Last Updated on November 8, 2023 by Aimed Alliance
